A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada-Clinical Trials Group Trial, MA.12)

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 283-290

  Bramwell, V H C ^a   Pritchard, K I ^b   Tu, D ^c   Tonkin, K ^d   Vachhrajani, H ^e   Vandenberg, T A ^f   Robert, J ^g   Arnold, A ^h   O'Reilly, S E ⁱ   Graham, B ^c   Shepherd, L ^c  

^a TOM BAKER CANCER CENTRE   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c Clinical Trials Group   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e Saskatoon Cancer Center   (Canada)

^f LONDON REGIONAL CANCER PROGRAM   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h JURAVINSKI CANCER CENTRE   (Canada)

ⁱ BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Early breast cancer; Premenopausal; Tamoxifen following chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; ALOPECIA; AMENORRHEA; ARTHRALGIA; ARTICLE; BLOOD DISEASE; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COUGHING; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; EDEMA; ENDOCRINE DISEASE; FEMALE; FIBROSIS; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HOT FLUSH; HUMAN; INFECTION; INSOMNIA; LETHARGY; LEUKOCYTE; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEURALGIA; NEUROLOGIC DISEASE; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PREMENOPAUSE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; TREATMENT PLANNING; TREND STUDY; UROGENITAL TRACT DISEASE; VAGINITIS; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECT; LYMPHADENECTOMY; MASTECTOMY; METHODOLOGY; MIDDLE AGED; MORTALITY; ORGANIZATION; PATHOLOGY; SURVIVAL; TIME;

ACADEMIES AND INSTITUTES; ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANADA; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPH NODE EXCISION; MASTECTOMY; MIDDLE AGED; PLACEBOS; PREMENOPAUSE; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS;

EID: 77951927588     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp326     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 71-85.
2. Albain KS, Green SJ, Ravdin PM et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 2002; 21: 37a (Abstr 143).
3. Osborne CK. Effects of estrogens and antiestrogens on cell proliferation: implications for the treatment of breast cancer. Cancer Treat Res 1988; 39: 111-129.
4. Goldenberg GJ, Froese EK. Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro. Biochem Pharmacol 1985; 34: 763-770.
5. Walshe JM, Neelima D, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006; 24: 5769-5779.
6. Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651-2658.
7. Fisher B, Anderson S, Tan-Chiu E et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19: 931-942.
8. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006; 24: 1332-1341.
9. Hutchins LF, Green SJ, Ravdin PM et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 2005; 23: 8313-8321.
10. Morales L, Canney P, Dyczka J et al. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomized phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. Eur J Cancer 2007; 43: 331-340.
11. Bramwell VHC, Pritchard KI. Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study? Eur J Cancer 1999; 35: 1625-1627.
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
13. Boccardo F, Rubagotti A, Amoroso D et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000; 18: 2718-2727.
14. Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002; 20: 4628-4635.
15. Jakesz R, Hausmaninger H, Kubista E et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002; 20: 4621-4627.
16. Regan MM, Pagani O, Walley B et al. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 2008; 19: 1213-1215.
17. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451-1467.
18. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002; 359: 2131-2139.
19. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women wit primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
20. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271.
21. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
22. Partridge AH, LaFountain A, Mayer E et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26: 556-562.
23. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 15: 602-606.
24. Barron TI, Connolly RM, Bennett K et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007; 109: 832-839.
25. McCowan D, Shearer J, Donnan PT et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008; 99: 1763-1768.
26. Kahn KL. Moving research from bench to bedside to community: there is still more to do. J Clin Oncol 2008; 26: 523-526.
27. Rae JM, Sikora MJ, Henry NL et al. Cytochrome p450 2D6 activity predicts adherence to tamoxifen therapy. Breast Cancer Res Treat 2007; 106: S21 (Abstr 77).
28. Tchen N, Juffs HG, Downie FP et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003; 21: 4175-4183.
29. Fisher B, Costantino JP, Redmond CK et al. Endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-537.
30. Partridge AH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol 2006; 17: 183-184.